FDA has issued a black box warning for tofacitinib and upadacitinib about an increased risk of thrombosis, including MI, stroke, arterial thrombosis, DVT, PE, and death.

In 2023, a new subcutaneous formulation of infliximab became available.

Buisson A et al. Clin Gastroenterol Hepatol. [PMID: 35987302]

Vedolizumab is approved for administration as both an intravenous and subcutaneous formulation.

Lim SH et al. Inflamm Bowel Dis. [PMID: 37603730]